Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

Fig. 3

a Waterfall plot demonstrating percent change from baseline in target tumor dimensions (best response, n = 19); b A representative image of JAK2 amplification; c JAK2 amplification is present in six patients: four Hodgkin lymphoma and two primary mediastinal large B-cell lymphoma; d Three of six patients with JAK2 amplification achieved partial response or stable disease, whereas three Hodgkin lymphoma patients without JAK2 amplification showed disease progression

Back to article page